Author + information
- Mohit Turagam,
- Venkat Lakshmi Kishan Vuddanda,
- Valay Parikh,
- Poonam Velagapudi,
- Mohammad-Ali Jazayeri,
- Madhav Lavu,
- Donita Atkins,
- Sudharani Bommana,
- Andrea Natale,
- Luigi Di Biase,
- Madhu Reddy,
- Jie Cheng,
- Krzysztof Bartus,
- Randall Lee and
- Dhanunjaya Lakkireddy
Background: The LARIAT device is a percutaneous endo-epicardial left atrial appendage (LAA) exclusion system that is currently performed in high risk atrial fibrillation (AF) patients intolerant to oral anticoagulation for stroke prevention and maybe reduction of AF burden.
Methods: A comprehensive search was performed in PubMed, EBSCO and Google Scholar databases for studies reporting success and adverse events with the LARIAT system. Studies reporting <10 patients were excluded from the analysis. Meta-analysis was carried out using MedCalc software using random effects model. Success and adverse event rates were adjusted and calculated per 100 procedures.
Results: A total of 8 studies including 1,232 patients were included. Procedural success was defined as <1mm leak on transesophageal echocardiography. Table 1 demonstrates procedural success and leaks at 3 month follow up. Death, pericardial tamponade, cardiac perforation and pericarditis were seen in 1.3%, 2%, 1.5% and 2.6% respectively. Table 2 demonstrates early (<30 days) and late (>30 days) complications with LARIAT.
Conclusions: LARIAT system appears to be highly efficacious with 91% achieving LAA exclusion (<1 mm leak) on follow up. Pericarditis, pericardial effusion and perforation were the most common complications and occurred in 1.5-2.6% of patients. Further prospective registries are required to demonstrate efficacy and safety of the LARIAT system.
Poster Hall, Hall C
Saturday, March 18, 2017, 3:45 p.m.-4:30 p.m.
Session Title: Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues
Abstract Category: 6. Arrhythmias and Clinical EP: Other
Presentation Number: 1236-094
- 2017 American College of Cardiology Foundation